177Lu-DOTA-EB-TATE Trial for Metastatic Hurthle-Cell Thyroid Cancer Initiated
A clinical trial is underway to evaluate 177Lu-DOTA-EB-TATE in adult patients with metastatic Hurthle-cell thyroid cancer.
Asset / Drug
Drug and asset intelligence for Metastatic Hurthle-Cell with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Radioactive Drug Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.